Spinal Muscular Atrophy Medicine Market Report

China Spinal Muscular Atrophy Medicine Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 22, 2022
  • PAGES：227
  • REPORT CODE：GMM1081050
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the China Spinal Muscular Atrophy Medicine market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Spinal Muscular Atrophy Medicine market. Detailed analysis of key players, along with key growth strategies adopted by Spinal Muscular Atrophy Medicine industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Genzyme Corporation

    • WAVE Life Sciences Ltd

    • Sarepta Therapeutics, Inc

    • Novartis AG

    • F Hoffmann-La Roche Ltd

    • Bioblast Pharma Ltd

    • AveXis, Inc

    • Neurodyn Inc

    • Vybion, Inc

    • Astellas Pharma Inc

    • GMP-Orphan SAS

    • Cytokinetics, Inc 24

    • Neurotune AG

    • Ionis Pharmaceuticals, Inc

    • Genethon

    • Longevity Biotech, Inc

    • Voyager Therapeutics, Inc

    By Type:

    • LMI-070

    • ND-602

    • NT-1654

    • Nusinersen

    • NXD-30001

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Spinal Muscular Atrophy Medicine Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of LMI-070 from 2016 to 2027

    • 1.3.2 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of ND-602 from 2016 to 2027

    • 1.3.3 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of NT-1654 from 2016 to 2027

    • 1.3.4 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Nusinersen from 2016 to 2027

    • 1.3.5 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of NXD-30001 from 2016 to 2027

    • 1.3.6 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Others from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Hospital from 2016 to 2027

    • 1.4.2 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Clinic from 2016 to 2027

    • 1.4.3 China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Others from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Spinal Muscular Atrophy Medicine Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Spinal Muscular Atrophy Medicine by Major Types

    • 3.4.1 Market Size and Growth Rate of LMI-070

    • 3.4.2 Market Size and Growth Rate of ND-602

    • 3.4.3 Market Size and Growth Rate of NT-1654

    • 3.4.4 Market Size and Growth Rate of Nusinersen

    • 3.4.5 Market Size and Growth Rate of NXD-30001

    • 3.4.6 Market Size and Growth Rate of Others

    4 Segmentation of Spinal Muscular Atrophy Medicine Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Spinal Muscular Atrophy Medicine by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Spinal Muscular Atrophy Medicine in Hospital

    • 4.4.2 Market Size and Growth Rate of Spinal Muscular Atrophy Medicine in Clinic

    • 4.4.3 Market Size and Growth Rate of Spinal Muscular Atrophy Medicine in Others

    5 Market Analysis by Regions

    • 5.1 China Spinal Muscular Atrophy Medicine Production Analysis by Regions

    • 5.2 China Spinal Muscular Atrophy Medicine Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 6.1 North China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 6.2 North China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    7 Central China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 7.1 Central China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 7.2 Central China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    8 South China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 8.1 South China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 8.2 South China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    9 East China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 9.1 East China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 9.2 East China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    10 Northeast China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 10.1 Northeast China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 10.2 Northeast China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    11 Southwest China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 11.1 Southwest China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 11.2 Southwest China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    12 Northwest China Spinal Muscular Atrophy Medicine Landscape Analysis

    • 12.1 Northwest China Spinal Muscular Atrophy Medicine Landscape Analysis by Major Types

    • 12.2 Northwest China Spinal Muscular Atrophy Medicine Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Genzyme Corporation

      • 13.1.1 Genzyme Corporation Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 WAVE Life Sciences Ltd

      • 13.2.1 WAVE Life Sciences Ltd Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Sarepta Therapeutics, Inc

      • 13.3.1 Sarepta Therapeutics, Inc Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 Novartis AG

      • 13.4.1 Novartis AG Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 F Hoffmann-La Roche Ltd

      • 13.5.1 F Hoffmann-La Roche Ltd Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 Bioblast Pharma Ltd

      • 13.6.1 Bioblast Pharma Ltd Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 AveXis, Inc

      • 13.7.1 AveXis, Inc Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 Neurodyn Inc

      • 13.8.1 Neurodyn Inc Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    • 13.9 Vybion, Inc

      • 13.9.1 Vybion, Inc Company Profile and Recent Development

      • 13.9.2 Market Performance

      • 13.9.3 Product and Service Introduction

    • 13.10 Astellas Pharma Inc

      • 13.10.1 Astellas Pharma Inc Company Profile and Recent Development

      • 13.10.2 Market Performance

      • 13.10.3 Product and Service Introduction

    • 13.11 GMP-Orphan SAS

      • 13.11.1 GMP-Orphan SAS Company Profile and Recent Development

      • 13.11.2 Market Performance

      • 13.11.3 Product and Service Introduction

    • 13.12 Cytokinetics, Inc 24

      • 13.12.1 Cytokinetics, Inc 24 Company Profile and Recent Development

      • 13.12.2 Market Performance

      • 13.12.3 Product and Service Introduction

    • 13.13 Neurotune AG

      • 13.13.1 Neurotune AG Company Profile and Recent Development

      • 13.13.2 Market Performance

      • 13.13.3 Product and Service Introduction

    • 13.14 Ionis Pharmaceuticals, Inc

      • 13.14.1 Ionis Pharmaceuticals, Inc Company Profile and Recent Development

      • 13.14.2 Market Performance

      • 13.14.3 Product and Service Introduction

    • 13.15 Genethon

      • 13.15.1 Genethon Company Profile and Recent Development

      • 13.15.2 Market Performance

      • 13.15.3 Product and Service Introduction

    • 13.16 Longevity Biotech, Inc

      • 13.16.1 Longevity Biotech, Inc Company Profile and Recent Development

      • 13.16.2 Market Performance

      • 13.16.3 Product and Service Introduction

    • 13.17 Voyager Therapeutics, Inc

      • 13.17.1 Voyager Therapeutics, Inc Company Profile and Recent Development

      • 13.17.2 Market Performance

      • 13.17.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of LMI-070 from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of ND-602 from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of NT-1654 from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Nusinersen from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of NXD-30001 from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Hospital from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Clinic from 2016 to 2027

    • Figure China Spinal Muscular Atrophy Medicine Market Size and Growth Rate of Others from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Spinal Muscular Atrophy Medicine Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Spinal Muscular Atrophy Medicine

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Spinal Muscular Atrophy Medicine by Different Types from 2016 to 2027

    • Table Consumption Share of Spinal Muscular Atrophy Medicine by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of LMI-070

    • Figure Market Size and Growth Rate of ND-602

    • Figure Market Size and Growth Rate of NT-1654

    • Figure Market Size and Growth Rate of Nusinersen

    • Figure Market Size and Growth Rate of NXD-30001

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Spinal Muscular Atrophy Medicine by Different End-Users from 2016 to 2027

    • Table Consumption Share of Spinal Muscular Atrophy Medicine by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Figure Market Size and Growth Rate of Others

    • Table China Spinal Muscular Atrophy Medicine Production by Regions

    • Table China Spinal Muscular Atrophy Medicine Production Share by Regions

    • Figure China Spinal Muscular Atrophy Medicine Production Share by Regions in 2016

    • Figure China Spinal Muscular Atrophy Medicine Production Share by Regions in 2021

    • Figure China Spinal Muscular Atrophy Medicine Production Share by Regions in 2027

    • Table China Spinal Muscular Atrophy Medicine Consumption by Regions

    • Table China Spinal Muscular Atrophy Medicine Consumption Share by Regions

    • Figure China Spinal Muscular Atrophy Medicine Consumption Share by Regions in 2016

    • Figure China Spinal Muscular Atrophy Medicine Consumption Share by Regions in 2021

    • Figure China Spinal Muscular Atrophy Medicine Consumption Share by Regions in 2027

    • Table North China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table North China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table North China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table North China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure North China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table Central China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table Central China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table Central China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table Central China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure Central China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table South China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table South China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table South China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table South China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure South China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table East China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table East China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table East China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table East China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure East China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table Northeast China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table Northeast China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table Northeast China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table Northeast China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure Northeast China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table Southwest China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table Southwest China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table Southwest China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table Southwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure Southwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table Northwest China Spinal Muscular Atrophy Medicine Consumption by Types from 2016 to 2027

    • Table Northwest China Spinal Muscular Atrophy Medicine Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2016

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2021

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by Types in 2027

    • Table Northwest China Spinal Muscular Atrophy Medicine Consumption by End-Users from 2016 to 2027

    • Table Northwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2016

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2021

    • Figure Northwest China Spinal Muscular Atrophy Medicine Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Genzyme Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genzyme Corporation

    • Figure Sales and Growth Rate Analysis of Genzyme Corporation

    • Figure Revenue and Market Share Analysis of Genzyme Corporation

    • Table Product and Service Introduction of Genzyme Corporation

    • Table Company Profile and Development Status of WAVE Life Sciences Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of WAVE Life Sciences Ltd

    • Figure Sales and Growth Rate Analysis of WAVE Life Sciences Ltd

    • Figure Revenue and Market Share Analysis of WAVE Life Sciences Ltd

    • Table Product and Service Introduction of WAVE Life Sciences Ltd

    • Table Company Profile and Development Status of Sarepta Therapeutics, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sarepta Therapeutics, Inc

    • Figure Sales and Growth Rate Analysis of Sarepta Therapeutics, Inc

    • Figure Revenue and Market Share Analysis of Sarepta Therapeutics, Inc

    • Table Product and Service Introduction of Sarepta Therapeutics, Inc

    • Table Company Profile and Development Status of Novartis AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG

    • Figure Sales and Growth Rate Analysis of Novartis AG

    • Figure Revenue and Market Share Analysis of Novartis AG

    • Table Product and Service Introduction of Novartis AG

    • Table Company Profile and Development Status of F Hoffmann-La Roche Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche Ltd

    • Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche Ltd

    • Figure Revenue and Market Share Analysis of F Hoffmann-La Roche Ltd

    • Table Product and Service Introduction of F Hoffmann-La Roche Ltd

    • Table Company Profile and Development Status of Bioblast Pharma Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bioblast Pharma Ltd

    • Figure Sales and Growth Rate Analysis of Bioblast Pharma Ltd

    • Figure Revenue and Market Share Analysis of Bioblast Pharma Ltd

    • Table Product and Service Introduction of Bioblast Pharma Ltd

    • Table Company Profile and Development Status of AveXis, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AveXis, Inc

    • Figure Sales and Growth Rate Analysis of AveXis, Inc

    • Figure Revenue and Market Share Analysis of AveXis, Inc

    • Table Product and Service Introduction of AveXis, Inc

    • Table Company Profile and Development Status of Neurodyn Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Neurodyn Inc

    • Figure Sales and Growth Rate Analysis of Neurodyn Inc

    • Figure Revenue and Market Share Analysis of Neurodyn Inc

    • Table Product and Service Introduction of Neurodyn Inc

    • Table Company Profile and Development Status of Vybion, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Vybion, Inc

    • Figure Sales and Growth Rate Analysis of Vybion, Inc

    • Figure Revenue and Market Share Analysis of Vybion, Inc

    • Table Product and Service Introduction of Vybion, Inc

    • Table Company Profile and Development Status of Astellas Pharma Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma Inc

    • Figure Sales and Growth Rate Analysis of Astellas Pharma Inc

    • Figure Revenue and Market Share Analysis of Astellas Pharma Inc

    • Table Product and Service Introduction of Astellas Pharma Inc

    • Table Company Profile and Development Status of GMP-Orphan SAS

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GMP-Orphan SAS

    • Figure Sales and Growth Rate Analysis of GMP-Orphan SAS

    • Figure Revenue and Market Share Analysis of GMP-Orphan SAS

    • Table Product and Service Introduction of GMP-Orphan SAS

    • Table Company Profile and Development Status of Cytokinetics, Inc 24

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cytokinetics, Inc 24

    • Figure Sales and Growth Rate Analysis of Cytokinetics, Inc 24

    • Figure Revenue and Market Share Analysis of Cytokinetics, Inc 24

    • Table Product and Service Introduction of Cytokinetics, Inc 24

    • Table Company Profile and Development Status of Neurotune AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Neurotune AG

    • Figure Sales and Growth Rate Analysis of Neurotune AG

    • Figure Revenue and Market Share Analysis of Neurotune AG

    • Table Product and Service Introduction of Neurotune AG

    • Table Company Profile and Development Status of Ionis Pharmaceuticals, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ionis Pharmaceuticals, Inc

    • Figure Sales and Growth Rate Analysis of Ionis Pharmaceuticals, Inc

    • Figure Revenue and Market Share Analysis of Ionis Pharmaceuticals, Inc

    • Table Product and Service Introduction of Ionis Pharmaceuticals, Inc

    • Table Company Profile and Development Status of Genethon

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genethon

    • Figure Sales and Growth Rate Analysis of Genethon

    • Figure Revenue and Market Share Analysis of Genethon

    • Table Product and Service Introduction of Genethon

    • Table Company Profile and Development Status of Longevity Biotech, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Longevity Biotech, Inc

    • Figure Sales and Growth Rate Analysis of Longevity Biotech, Inc

    • Figure Revenue and Market Share Analysis of Longevity Biotech, Inc

    • Table Product and Service Introduction of Longevity Biotech, Inc

    • Table Company Profile and Development Status of Voyager Therapeutics, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Voyager Therapeutics, Inc

    • Figure Sales and Growth Rate Analysis of Voyager Therapeutics, Inc

    • Figure Revenue and Market Share Analysis of Voyager Therapeutics, Inc

    • Table Product and Service Introduction of Voyager Therapeutics, Inc


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US